Inspire Medical Systems authorizes $200 million share buyback program

Inspire Medical Systems Inc. (NYSE: INSP) announced that its board of directors has authorized the repurchase of up to $200 million of the company's outstanding common stock. The medical technology company develops solutions for patients with obstructive sleep apnea.

"During the second quarter, we initiated the full U.S. launch of Inspire V, our next-generation neurostimulation system," said Tim Herbert, chairman and chief executive officer. "The continued financial strength of the company allows us to return capital to stockholders while we continue to invest for future growth."

The company will determine the timing, manner, price and amount of repurchases at its discretion. Purchases may be conducted through open market transactions, privately negotiated transactions, or other means. The program expires on August 7, 2027, though it may be modified, suspended or discontinued at any time.

In determining capital allocation for share repurchases, the company considers its business performance, cash position, market conditions and stock price. The company is not obligated to repurchase any specific number of shares.

Inspire develops neurostimulation technology for treating moderate to severe obstructive sleep apnea. The company's Inspire therapy received approval from the FDA, EU MDR and PDMA.

You May Also Be Interested In

• Shell pauses $3 billion share buyback program due to ARC deal
• Cuprina Holdings regains compliance with NASDAQ listing requirements
• Park Ha Biological prices $2 million registered direct offering